Armata Pharmaceuticals, Inc.
ARMP · AMEX
Company research
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) is a late clinical-stage biotechnology company headquartered in Marina del Rey, California, focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology platform. The company is advancing a broad pipeline of natural and synthetic phage candidates, including its lead clinical candidates AP-SA02 for Staphylococcus aureus bacteremia, AP-PA02 targeting Pseudomonas aeruginosa, and AP-PA03 for the treatment of pneumonia — addressing pathogens on the World Health Organization's global priority list. In addition, Armata has a research collaboration agreement with Merck & Co. to develop synthetic bacteriophage candidates targeting undisclosed infectious disease agents. Led by CEO Deborah L. Birx, M.D., and operating as a subsidiary of Innoviva, Inc., Armata is positioned as a pioneering innovator in the growing field of phage therapy, seeking to provide targeted solutions amid the global antimicrobial resistance crisis.
Research reports
Brokerage-hosted analyst consensus page summarizing two third-party Strong Buy ratings with a 15 price target, arguing that AP-PA02 and AP-SA02 have promising trial data and commercial potential while flagging heavy funding needs, trial failure risk and questions over data robustness as key constraints on the investment case.
CirclFi Research Team · June 6, 2026Should You Buy Armata Pharmaceuticals, Inc. Stock in 2026?Quantitative multi-model valuation note comparing seven active fair-value frameworks, concluding that five models see ARMP as overvalued, with a low 3.7/10 quality score but limited “value trap” risk, and highlighting large upside in scenario-based bull cases versus significant uncertainty and very wide dispersion in intrinsic value estimates.
Expert-Time / Newser Market Analysis · May 23, 2026Armata Pharmaceuticals (ARMP) Q1 2026 Earnings: Steep EPS Miss as Clinical-Stage Biotech Continues Heavy R&D Spending - Cost Structure ReviewEarnings-focused research note reviewing ARMP’s Q1 2026 results, highlighting a massive EPS miss and zero revenue tied to aggressive R&D spending on its phage pipeline, discussing cash-burn and funding-risk trade-offs, and stressing that near-term share performance hinges more on upcoming clinical catalysts than quarterly financials.
Intellectia AI™ · April 17, 2026Should You Buy Armata Pharmaceuticals Inc (ARMP) Today? Analysis, Price Targets, and 2026 Outlook.AI-driven “Should I Buy” report that rates ARMP as a Hold for long-term beginner investors, noting severe year-over-year deterioration in revenue, net income and EPS, mixed technical signals, and analyst price target upgrades from 9 to 15 and 15 to 20 based on AP-SA02’s perceived paradigm-shifting potential and forthcoming Phase 3 program.
Macroaxis · March 13, 2026Armata Pharmaceuticals Stock AnalysisComprehensive stock analysis framing ARMP as undervalued versus an intrinsic value estimate of 11.79 and a 15.0 target price, but emphasizing high leverage, weak profitability, elevated probability of financial distress, insider share concentration and volatile technical profile, making the name appropriate only for investors willing to tolerate substantial downside risk.
Simply Wall St · September 23, 2025Armata Pharmaceuticals (NYSEAM:ARMP) - Stock AnalysisFundamental overview of ARMP as a clinical-stage bacteriophage developer with very weak Snowflake scores across valuation, future growth, past performance, financial health and dividends, documenting highly negative margins, persistent losses, high debt-to-equity and limited analyst coverage even as it notes strong one-year share price gains versus biotech peers.